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Abstract: Hormone therapies and vigabatrin are first-line agents in infantile spasms, but more than
one-third of patients fail to respond to these treatments. This was a retrospective study of patients
with infantile spasms who were treated between January 2005 and December 2017. We analyzed the
response rates of initial treatment and second-line treatment. Responders were defined as those in
whom cessation of spasms was observed for a period of at least one month, within 2 weeks of treatment
initiation. Regarding the response rate to initial treatment, combination therapy of vigabatrin with
prednisolone showed a significantly better response than that of vigabatrin monotherapy (55.3%
vs. 39.1%, p = 0.037). Many drugs, such as clobazam, topiramate, and levetiracetam, were used as
second-line agents after the failure of vigabatrin. Among these, no antiepileptic drug showed as good
a response as prednisolone. For patients who used prednisolone, the proportion of responders was
significantly higher in the higher-dose group (≥40 mg/day) than in the lower-dose group (66.7% vs.
12.5%, p = 0.028). Further studies of combination therapy to assess dosage protocols and long-term
outcomes are needed.
Keywords: Infantile spasms; First-line treatment; Combination of vigabatrin with prednisolone;
Higher dose of prednisolone
1. Introduction
Infantile spasms is a rare and severe seizure disorder that is difficult to treat [1]. Its incidence
ranges from 2 to 3.5 cases per 10,000 live births, with a peak onset at 3 to 7 months of age [2]. Infantile
spasms possess three features: epileptic spasms, hypsarrhythmia on electroencephalogram (EEG), and
developmental regression [3]. Delayed treatment can lead to poor outcomes; Therefore, timely and
appropriate treatment is important [4].
Hormonal therapies (adrenocorticotropic hormone (ACTH) or prednisolone] and vigabatrin are
the two main treatments that are considered “standard” for infantile spasms [5]. Hormonal treatment
was first used in the treatment of this disorder in 1958, and has been shown to be effective in the
cessation of spasms and resolution of EEG abnormalities [6]. Vigabatrin, an inhibitor of γ-aminobutyric
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acid transaminase, was approved by the US Food and Drug Administration for the treatment of
infantile spasms in 2009 [7].
In the United Kingdom Infantile Spasms Study (UKISS) trial, hormonal therapies showed a higher
rate of cessation of spasms at 2 weeks than vigabatrin (73% vs. 54%, p= 0·043) [8]. In addition, according
to the 2012 American Academy of Neurology and Child Neurology Society evidence-based guideline,
ACTH is more effective than vigabatrin, excluding patients with tuberous sclerosis complex [9].
However, some studies did not show significant differences in long-term efficacy between hormonal
therapies and vigabatrin [10,11].
More than one-third of patients fail to respond, even if treated with standard therapies. In addition,
all other antiepileptic drugs (e.g., valproic acid, pyridoxine, topiramate, zonisamide, and levetiracetam)
have insufficient evidence for treating infantile spasms, when used as second-line therapy or add-on
therapy [12–17]. Recently, there has been ongoing research on the additional efficacy of using
vigabatrin and steroid combination treatment. Some studies have shown a short-term response rate
that is significantly higher with combination treatment than with steroids alone [18,19], but such
advantages are still unclear.
Therefore, we aimed to assess the efficacy of vigabatrin and steroid combination treatment in
comparison with standard monotherapy as first-line treatments for infantile spasms. We also evaluated
the response rates of various secondary medications in patients in whom these first-line treatments
were ineffective.
2. Experimental Section
2.1. Study Design and Subjects
We conducted a retrospective analysis of the medical records of patients with infantile spasms
who were treated and followed up for at least 3 months in a university-affiliated tertiary care hospital
in Korea between January 2005 and December 2017. This study was approved by the Institutional
Review Board (IRB No. 4-2016-0822) of Severance Hospital, and conducted in accordance with the
principles of the STROBE statement which stands for an international, collaborative initiative of
epidemiologists, methodologists, statisticians, researchers and journal editors involved in the conduct
and dissemination of observational studies, with the common aim of STrengthening the Reporting of
OBservational studies in Epidemiology. Written informed consent was waived by IRB because this
study was based on retrospective medical record data, and all data were anonymized.
The inclusion criteria were as follows: a diagnosis of clinical spasms and EEG demonstrating
features of hypsarrhythmia or modified hypsarrhythmia in patients between the ages of 2 and
12 months.
The exclusion criteria included the following: patients with uncertain diagnosis, patients with
early infantile epileptic encephalopathy, patients who had concurrent treatment in other hospitals,
patients with incomplete medical records, and patients with no follow-up visit.
2.2. Outcome Measurement
We considered vigabatrin and oral corticosteroids (all the cases in our analysis had been treated
with prednisolone) as the standard therapies in this study. ACTH was excluded because of the lack of
availability of this drug in Korea [20]. All other medications were considered non-standard therapies
(e.g., clobazam, topiramate, valproic acid, levetiracetam, phenobarbital, zonisamide, clonazepam,
oxcarbazepine, and a ketogenic diet). We analyzed the efficacy of the following four treatment
groups: vigabatrin, prednisolone, combination therapy with vigabatrin and prednisolone, and
non-standard therapy.
The primary clinical outcome was the response to initial treatment. Responders were defined
as those whose clinical spasms were resolved within 2 weeks of treatment, and in whom this effect
was sustained for at least 4 weeks [18,21]. Patients who did not have complete resolution of clinical
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spasms within 2 weeks of treatment or those in whom efficacy was sustained for less than 4 weeks
were considered non-responders. In addition, we investigated the relapse rate of each treatment group.
Clinical relapse was defined as the recurrence of clinical spasms within 6 months following a previous
response to treatment.
As the secondary clinical outcome, we analyzed the responses to second-line treatment.
Non-responders to the first-line treatment were the subjects of this analysis. The definitions of
responder and non-responder are the same as those used for the primary clinical outcome. However,
clinical relapse was not considered because the interval of follow-up for each patient was variable.
We collected the following data for each patient: sex, birthdate, report of EEG, presence of seizures
prior to spasms, infantile spasm medication and dosage, age at spasm onset, first hospital visit date,
age at initiation of treatment, treatment lag time (time from spasm onset to initiation of treatment), and
time to the cessation of spasms.
2.3. Statistical Analysis
The demographic and clinical characteristics by treatment group were compared using Chi-square
tests or Fisher’s exact test for categorical data, and Kruskal-Wallis tests for continuous data.
The associations of clinical characteristics with treatment response were assessed using Chi-square tests
or Fisher’s exact test. Next, the association between each treatment and response was assessed through
multivariable logistic regression models that adjusted for factors found to be potentially predictive of
response to therapy [22].
All statistical analyses were performed using SPSS® (IBM Corp. Released 2016. IBM SPSS
Statistics for Windows, Version 24.0. Armonk, NY, USA: IBM Corp.), and two-sided tests with a
significance level of α = 0.05 were used.
3. Results
3.1. Patient Characteristics
Figure 1 shows the flow chart of patients included in this study. Beginning with 526 patients,
155 patients were excluded, leaving 371 patients enrolled in our study.
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3.2. First-Line Treatment
Among the 371 included patients, vigabatrin was used in 271 patients (73.0%), prednisolone was
used in 6 patients (1.6%), combination therapy (vigabatrin and prednisolone) was used in 47 patients
(12.7%), and non-standard therapy was used in 47 patients (12.7%). Seizures prior to spasms, age at
spasm onset, age at treatment, and etiology were not different in the four treatment groups (Table 1).
However, the treatment lag time was significantly different in each group, which may reflect prescription
bias (12.0 (interquartile range (IQR), 5.0–29.0) vs. 7.0 (IQR 4.3–19.5) vs. 20.0 (IQR, 11.5–43.0) vs. 20.0
(IQR 7.0–56.0) days, p = 0.012, for the treatment groups, respectively).
Table 1. Baseline characteristics by type of first-line treatment.
Characteristic
Treatment Group a p Value
Vigabatrin
n = 271
Prednisolone
n = 6
Vigabatrin +
Prednisolone
n = 47
Non-Standard
n = 47
Total
n = 371
Sex
Male
Female
163 (60.1)
108 (39.9)
1 (16.7)
5 (83.3)
21 (44.7)
26 (55.3)
30 (63.8)
17 (36.2)
215 (58.0)
156 (42.0) 0.032
†,*
Presence of seizure
history 97 (35.8) 0 (0.0) 16 (34.0) 15 (31.9) 128 (34.5) 0.320
†
Age at spasm onset, mo. 5.8 (4.4, 7.3) 7.7 (5.1, 8.7) 5.7 (4.4, 6.7) 5.7 (4.4, 7.4) 5.8 (4.4, 7.3) 0.719 ‡
Age at treatment, mo. 6.6 (5.3, 8.1) 8.1 (5.4, 8.9) 6.6 (5.5, 8.0) 7.1 (5.3, 8.8) 6.6 (5.3, 8.2) 0.804 ‡
Lag time from spasm
onset to treatment, days
12.0
(5.0, 29.0)
7.0
(4.3, 19.5)
20.0
(11.5, 43.0)
20.0
(7.0, 56.0)
14.0
(5.0, 32.0) 0.012
‡,*
Etiology
Structural
Metabolic
Infection
Genetic
Unknown
87 (32.1)
23 (8.5)
6 (2.2)
7 (2.6)
148 (54.6)
1 (16.7)
0 (0)
0 (0)
0 (0)
5 (83.3)
15 (31.9)
2 (4.3)
0 (0)
1 (2.1)
29 (61.7)
12 (25.5)
2 (4.3)
1 (2.1)
1 (2.1)
31 (66.0)
115 (31.0)
27 (7.3)
7 (1.9)
9 (2.4)
213 (57.4)
0.938 §
a Values are n (%) or median (Q1, Q3); mo., months. † Chi-square test; ‡ Kruskal-Wallis test; § Fisher’s exact test.
* p-value < 0.05.
Table 2 shows the response rates and periods from the start of treatment to response, and relapse
rates of the first-line treatments. One hundred and forty-one of the 371 (38.0%) patients with infantile
spasms responded to the initial treatment, with 106 out of 271 (39.1%) on vigabatrin, 4 out of 6
(66.7%) on prednisolone, 26 out of 47 (55.3%) on combination therapy, and 5 out of 47 (10.6%) on
non-standard therapy. When comparing response rates between each treatment group, the vigabatrin
group, prednisolone group, and combination group showed significantly better response rates than the
non-standard group (p < 0.001, p = 0.005, and p < 0.001, respectively). We did not observe differences in
the responses between the vigabatrin and prednisolone groups (p = 0.219) and between the combination
and prednisolone groups (p = 0.687). However, the response rate of the combination group was
significantly higher than that of the vigabatrin group (p = 0.037).
Table 2. Effect of first-line treatment on response.
Response to
Initial treatment a
Time to Cessation
of Spasms (days) b Relapse Rate
a
Treatment Responsen = 141
Non-Response
n = 230
Vigabatrin 106 (39.1) 165 (60.9) 5 (3, 9) 8 (7.5)
Prednisolone 4 (66.7) 2 (33.3) 4 (3, 7) 1 (25.0)
Vigabatrin +
prednisolone 26 (55.3) 21 (44.7) 5 (2, 9) 3 (11.5)
Non-standard 5 (10.6) 42 (89.4) 4 (2, 7) 2 (40.0)
a Values are n (%); b Values are median (Q1, Q3).
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The cohorts of first-line treatment responders and non-responders were evaluated for predictors
of outcome. There was no significant difference in response to first-line treatment when sex, age at
spasm onset, and age at treatment were evaluated. However, treatment lag time and seizures prior
to spasms were associated with response to therapy on univariate analysis (p < 0.001, and p = 0.030,
respectively). In the multivariable logistic regression, the risk ratio of response to treatment decreased
0.406-times (95% confidence interval (CI) 0.239–0.689) in patients with lag times >4 weeks, compared
with that in patients with lag times ≤4 weeks (p = 0.001). Patients with prior seizures were 0.593-times
(95% CI 0.371–0.949) less likely to respond to therapy than patients without prior seizures (p = 0.029).
Even after adjustment for treatment lag time and prior seizure history, comparisons of response rates
from each treatment group showed the same results (Table 3).
Table 3. Relative probability (relative risk) of response to treatment.
Characteristic Respondersn (%) p value
†
Crude
Risk Ratio
(95% CI)
Adjusted a
Risk Ratio
(95% CI)
Adjusted b
Risk Ratio
(95% CI)
Treatment
Vigabatrin 106 (39.1) REF REF REF
Prednisolone 4 (66.7) 0.219 3.113(0.560, 17.296)
2.602
(0.465, 14.560)
2.980
(0.523, 16.975)
Vigabatrin +
prednisolone 26 (55.3) 0.037 *
1.927
(1.032, 3.599)
1.929
(1.028, 3.620)
2.139
(1.124, 4.069)
Non-standard 5 (10.6) <0.001 * 0.185(0.071, 0.483)
0.179
(0.068, 0.468)
0.205
(0.078, 0.539)
Seizure history
No 102 (42.0) 0.030 * REF REF -
Yes 39 (30.5) 0.606(0.385, 0.954)
0.593
(0.371, 0.949) -
Lag time
≤4 weeks 116 (43.8) <0.001 * REF - REF
>4 weeks 25 (23.6) 0.396(0.238, 0.660) -
0.406
(0.239, 0.689)
REF, reference group. † Chi-square test * p-value <0.05. a Model including treatment and seizures before infantile
spasms as covariates. b Model including treatment and lag time as covariates.
3.3. Second-Line Treatment
Various drugs were used when vigabatrin, the most frequently used first-line treatment, failed.
A high percentage of patients (128/165, 77.6%) received the following three drugs: clobazam, topiramate,
or prednisolone. Specifically, among these 165 patients, 65 patients (39.4%) received clobazam,
43 patients (26.1%) received topiramate, and 20 patients (12.1%) received prednisolone. The remaining
37 patients (22.4%) received other antiepileptic drugs such as levetiracetam (11), zonisamide (8),
phenobarbital (8), valproic acid (3), clonazepam (1), lamotrigine (1), or vigabatrin up-titration (5).
Overall, 38 out of the 165 patients (23.0%) were observed to be spasm-free. Nine of the 20 patients
(45.0%) receiving prednisolone, 12 of the 65 patients (18.5%) receiving clobazam, and 9 of the 43 patients
(20.9%) receiving topiramate responded. Prednisolone showed a significantly higher response rate
than both clobazam (p = 0.035) and topiramate (p = 0.049). There was no significant difference between
the response rates of clobazam and topiramate (p = 0.751). The other patients who showed cessation of
spasms (n = 8) were as follows: two out of 11 patients who received levetiracetam, 1 out of 8 patients
who received zonisamide, and 5 patients who received up-titration of vigabatrin therapy. The responses
to second-line therapy in all first-line treatment failure groups are presented in Table 4.
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Table 4. Response rate to second-line treatment.
First-Line
Treatment
Second-Line
Treatment
Vigabatrin Prednisolone Non-Standard
Vigabatrin 5/5, 100%(up-titration) 9/20, 45% 24/140, 17%
Prednisolone 2/2, 100% - -
Vigabatrin + prednisolone 1/1, 100%(up-titration) - 2/20, 10%
Non-standard 13/31, 42% 0/1, 0% 2/10, 20%
3.4. Dosage of Prednisolone
We compared the efficacy of the higher dose (40–60 mg/day) of prednisolone with that of the lower
dose (<40 mg/day). In the prednisolone monotherapy group, all patients were treated with 20 mg/day
(lower dose), and 4 out of 6 of these patients responded. In the group of combination therapy with
vigabatrin and prednisolone, 81.8% (9 out of 11) of the patients in the higher dose group responded
compared to 47.2% (17 out of 36) of the patients in the lower dose group. However, this difference
was not statistically significant (p = 0.081). When prednisolone was used as the second-line therapy
after the failure of vigabatrin, the proportion of responders was significantly higher in the higher dose
group than that in the lower dose group (8/12, 66.7% vs. 1/8, 12.5%, p = 0.028) (Figure 2).
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4. Discussion
Optimized treatment for infa tile spa ms remains contr versial. The result of this study suggest
that an initial combination treatment of vigabatrin with prednisolone is more beneficial than vigabatrin
monotherapy for patients with infantile spasm. After adjusting for treatment lag time and prior
history of seizures, which were predictors of the response, the response rate with combination
therapy was almost twice that of vigabatrin alone. This result could be interpreted in the same
context as combination therapy yielding higher short-term response rates than hormonal treatment
alone [18,19]. Combination therapy could have a synergistic effect, and prevent treatment delay by
a rapid response [23]. Considering similar relapse rates and time to cessation of spasms between
the vigabatrin and combination therapy groups in our study, we propose that combination therapy
could be reco mended at the start of treatment. However, further studies of combination therapy
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focusing on long-term efficacy, safety, factors influencing the response, and optimized dosing protocols
(synchronous initiation or stepwise approach [24]) are needed.
In second-line treatments, which were used in cases of insufficient response to vigabatrin,
prednisolone showed a greater response rate than non-standard treatments (45% vs. 17%, p = 0.008).
In first-line prednisolone or combination treatment non-responders, additional vigabatrin (n = 2)
or up-titration of vigabatrin (n = 1) showed 100% response rates, whereas additional non-standard
treatment (n = 20) showed only a 10% response rate. These results were in agreement with a previous
prospective study that showed standard therapy, which had a different mechanism of action from the
initial treatment, was effective as a second-line treatment [13]. Although not as effective as standard
treatments, non-standard therapies (i.e., clobazam, topiramate, and levetiracetam) elicited responses in
some patients. After standard therapies have failed, these antiepileptic drugs can be considered as
treatment options. However, to provide more evidence to justify this conclusion, studies with large
patient cohorts are needed.
The response rate of prednisolone should be interpreted with caution because of the small sample
size (first-line monotherapy, 6; first-line combination therapy, 47; second-line therapy, 21) and different
dose protocols of prednisolone in our cohort of patients. Until 2015, our hospital patients tended to
receive lower doses because of concerns regarding prednisolone’s serious adverse reactions, such
as infection, sepsis, hypertension, adrenal insufficiency, growth retardation, and gastrointestinal
bleeding [9]. However, Chellamuthu et al. reported that high-dose (4 mg/kg/day) prednisolone
was more effective than standard dose (2 mg/kg/day) in spasm cessation at 14 days [25], and recent
guidelines by the Pediatric Epilepsy Research Consortium (PERC) also recommended a prednisolone
dosage of 10 mg four times daily [24]. When we analyzed response rates according to dosage of
prednisolone, 12.5% of patients receiving low-dose prednisolone responded, whereas 66.7% receiving
the high dose (≥40 mg/day) responded when used as second-line treatment after vigabatrin failure.
Higher-dose prednisolone (up to 60 mg/day) has been shown to be safe in various studies [1,8,26].
Thus, we propose that the higher dose of prednisolone could be recommended for all patients with
infantile spasms. Meanwhile, vigabatrin was administered at 50 mg/kg/day initially and increased to
100–150 mg/kg/day in most patients.
Our study has some limitations. First, as a nonrandomized, retrospective study, it was difficult to
control the dosage and duration of treatment accurately, in a manner that could be done in a prospective
study. However, our study does have an advantage of reflecting the clinical reality beyond randomized
controlled trials. In clinical practice, drug efficacy was not assessed until after 2 weeks of use, and many
patients were given additional drugs if the previous drug appeared ineffective. We assumed that the
second treatment had caused a response even though the first treatment continued to be used during
second-line treatment, and could have been responsible for the response observed. However, since two
drugs were co-administered, the effect of each drug could not be measured accurately. In this context,
we have been cautious in not overinterpreting our findings. Second, a response was defined as only the
cessation of spasms without considering EEG resolution. According to a recent study, hypsarrhythmia
is not seen in all patients with infantile spasms, and the presence or absence of hypsarrhythmia may not
have predictive value [27]. Typically, clinical spasms are associated with developmental regression [28],
which justifies our outcome measurement. Third, we did not identify distinct patient subsets that
showed a better response to combination therapy than to vigabatrin alone. Further study considering
each patient’s baseline characteristics, including etiology and developmental function, is needed.
Ultimately, this study had a larger number of patients for analysis than previous studies and
provided evidence of effective treatments for managing infantile spasms. Although there were several
limitations, it was meaningful that our study evaluated actual prescription patterns in clinical practice.
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